title: Zolpidem modified-release in insomnia.
abstract: Zolpidem modified-release (MR) is the first hypnotic agent to be marketed in an extended-release formulation. Zolpidem MR is a two-layered, biphasic release tablet indicated for the management of induction of sleep and sleep maintenance. The pharmacokinetics of the drug are similar to those of immediate-release zolpidem. Two double-blind, placebo-controlled, parallel-group trials demonstrated efficacy in adults and elderly patients treated with zolpidem MR for 3 weeks without significant impairment in next-day psychomotor functioning. The most common adverse effects with zolpidem MR were dizziness, somnolence, and headache. A starting dose of zolpidem MR 12.5 mg is recommended for adults and 6.25 mg for elderly patients.
authors.affiliation: Virginia Commonwealth University, Department of Pharmacy, Richmond, VA, USA. ckkirkwo@vcu.edu
authors.forename: Cynthia
authors.initials: C
authors.lastname: Kirkwood
authors.forename: Jason
authors.initials: J
authors.lastname: Neill
authors.forename: Ericka
authors.initials: E
authors.lastname: Breden